Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 4/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20491187 | 0.83 | HDAC6 (0.64) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL19710840 | 0.83 | VNN1 (0.61) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL20491534 | 0.82 | VNN1 (0.78) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL18286325 | 0.80 | VNN1 (1.00) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL20491522 | 0.79 | VNN1 (0.64) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL4730434 | 0.79 | HDAC3 (1.00) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL17813775 | 0.79 | HDAC3 (0.71) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL17814775 | 0.77 | VNN1 (0.63) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL18742508 | 0.77 | HDAC3 (0.78) | VNN1HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL16647259 | 0.77 | HDAC6 (0.58) | VNN1HDAC6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | VNN1 1112/4885HDAC6 1/4885HDAC3 7/4885 |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | VNN1 1112/4885HDAC6 1/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.